The impact of mepolizumab on the sputum level of eosinophil-derived protein in three cases of severe asthma

The impact of mepolizumab on the sputum level of eosinophil-derived protein in three cases of severe asthma

Bibliographic Details
Main Authors:	Toshiyuki Koya, Yosuke Kimura, Masachika Hayashi, Takashi Hasegawa, Toshiaki Kikuchi
Format:	Article
Language:	English
Published:	Elsevier 2020-10-01
Series:	Allergology International
Online Access:	http://www.sciencedirect.com/science/article/pii/S1323893020300435

Similar Items

Clinical usefulness of mepolizumab in severe eosinophilic asthma
by: Menzella F, et al.
Published: (2016-06-01)

Differential effects of short- and long-term treatment with mepolizumab on eosinophil kinetics in blood and sputum in eosinophilic asthma
by: Marwan Hassani, et al.
Published: (2021-08-01)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
by: Steven W. Yancey, et al.
Published: (2019-09-01)

Clinical efficacy of mepolizumab in the treatment of severe eosinophilic asthma in children
by: V. N. Drozdov, et al.
Published: (2020-11-01)

Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis
by: Takanori Numata, et al.
Published: (2019-10-01)

Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma
by: Terufumi Shimoda, et al.
Published: (2017-07-01)

Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma
by: Haldar P
Published: (2017-06-01)

Economic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma
by: Manuel David Gil-Sierra, et al.
Published: (2019-11-01)

Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life
by: Diego Bagnasco, et al.
Published: (2021-02-01)

Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes
by: Prazma CM, et al.
Published: (2021-06-01)

Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience
by: Gilda Varricchi, et al.
Published: (2017-01-01)

Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience
by: Rosalia Emma, et al.
Published: (2018-10-01)

Effectiveness and safety of mepolizumab in severe refractory eosinophilic asthma: results in clinical practice
by: Olalla Montero-Pérez, et al.
Published: (2019-05-01)

Eosinophils depletion therapy for severe asthma management following favorable response to mepolizumab
by: Osamu Matsuno, et al.
Published: (2019-01-01)

Experience with mepolizumab in adults with severe eosinophilic asthma: a case series from India
by: Venkata Nagarjuna Maturu, et al.
Published: (2021-08-01)

Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics
by: Mark C. Liu, et al.
Published: (2021-05-01)

Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma
by: Giovanna Elisiana Carpagnano, et al.
Published: (2021-03-01)

Real-life effectiveness of mepolizumab in patients with severe refractory eosinophilic asthma and multiple comorbidities
by: Claudia Crimi, et al.
Published: (2020-09-01)

Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab
by: Pelaia C, et al.
Published: (2017-10-01)

Clinical and economic comparison of utilization of reslizumab, mepolizumab and benralizumab in the treatment of severe eosinophilic asthma
by: S. K. Zyryanov, et al.
Published: (2020-12-01)

Severe eosinophilic asthma and aspirin-exacerbated respiratory disease associated to eosinophilic gastroenteritis treated with mepolizumab: a case report
by: C. Caruso, et al.
Published: (2020-04-01)

Efficacy and safety of mepolizumab in Korean patients with severe eosinophilic asthma from the DREAM and MENSA studies
by: Mi-Kyeong Kim, et al.
Published: (2021-03-01)

Characterization of low adherence population in asthma patients from Japan using Adherence Starts with Knowledge-12
by: Yuka Kimura, et al.
Published: (2020-01-01)

Treatment of eosinophilic myositis with mepolizumab
by: Saadia Waheed, et al.
Published: (2018-01-01)

The effect of mepolizumab, an anti-IL-5 monoclonal antibody, on eosinophilic otitis media associated with severe asthma
by: Yuki Maruyama, et al.
Published: (2020-08-01)

Predictors of the enhanced response to mepolizumab treatment for severe eosinophilic asthma: A retrospective, long-term study
by: Takanori Numata, et al.
Published: (2020-01-01)

Response to case report: Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy
by: I. J. Pouliquen, et al.
Published: (2017-11-01)

Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months
by: Kayser MZ, et al.
Published: (2021-07-01)

Effectiveness of mepolizumab for eosinophilic pneumonia following bronchial thermoplasty
by: Ryota Otoshi, et al.
Published: (2020-03-01)

Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts
by: Arian Ghassemian, et al.
Published: (2021-01-01)

Phenotypic analysis of asthma in Japanese athletes
by: Keisuke Tsukioka, et al.
Published: (2017-10-01)

Clinical-economic impact of mepolizumab in patients with severe hypereosinophilic asthma
by: Diego Bagnasco, et al.
Published: (2020-08-01)

Usefulness of induced sputum eosinophil count to assess severity and treatment outcome in asthma patients
by: Ankan Bandyopadhyay, et al.
Published: (2013-01-01)

Association of eosinophilic inflammation with FKBP51 expression in sputum cells in asthma.
by: Tomoko Tajiri, et al.
Published: (2013-01-01)

Safety and Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis
by: Ravi Ranjan Pradhan, et al.
Published: (2019-01-01)

Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease
by: Mkorombindo T, et al.
Published: (2019-08-01)

Precision medicine in COPD: review of mepolizumab for eosinophilic COPD
by: Gabriella Long, et al.
Published: (2018-12-01)

Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA
by: Frank C. Albers, et al.
Published: (2019-07-01)

A Case of Effective Mepolizumab Induction Therapy for Severe Eosinophilic Granulomatosis with Polyangiitis Diagnosed by Eosinophilic Cholecystitis and Interstitial Nephritis
by: Keita Hattori, et al.
Published: (2021-01-01)

Self-Administered Mepolizumab in the Management of Severe Asthma: Usability and Patient Acceptance
by: Miyokawa R, et al.
Published: (2020-09-01)